| Style | Citing Format |
|---|---|
| MLA | Sadeghi S, Kargar M. "Is There Association Between Clinically Relevant Toxicities of Pazopanib and Sunitinib With the Use of Weak Cyp3a4 and P-Gp Inhibitors?." European Journal of Clinical Pharmacology, vol. 77, no. 9, 2021, pp. 1427-1428. |
| APA | Sadeghi S, Kargar M (2021). Is There Association Between Clinically Relevant Toxicities of Pazopanib and Sunitinib With the Use of Weak Cyp3a4 and P-Gp Inhibitors?. European Journal of Clinical Pharmacology, 77(9), 1427-1428. |
| Chicago | Sadeghi S, Kargar M. "Is There Association Between Clinically Relevant Toxicities of Pazopanib and Sunitinib With the Use of Weak Cyp3a4 and P-Gp Inhibitors?." European Journal of Clinical Pharmacology 77, no. 9 (2021): 1427-1428. |
| Harvard | Sadeghi S, Kargar M (2021) 'Is There Association Between Clinically Relevant Toxicities of Pazopanib and Sunitinib With the Use of Weak Cyp3a4 and P-Gp Inhibitors?', European Journal of Clinical Pharmacology, 77(9), pp. 1427-1428. |
| Vancouver | Sadeghi S, Kargar M. Is There Association Between Clinically Relevant Toxicities of Pazopanib and Sunitinib With the Use of Weak Cyp3a4 and P-Gp Inhibitors?. European Journal of Clinical Pharmacology. 2021;77(9):1427-1428. |
| BibTex | @article{ author = {Sadeghi S and Kargar M}, title = {Is There Association Between Clinically Relevant Toxicities of Pazopanib and Sunitinib With the Use of Weak Cyp3a4 and P-Gp Inhibitors?}, journal = {European Journal of Clinical Pharmacology}, volume = {77}, number = {9}, pages = {1427-1428}, year = {2021} } |
| RIS | TY - JOUR AU - Sadeghi S AU - Kargar M TI - Is There Association Between Clinically Relevant Toxicities of Pazopanib and Sunitinib With the Use of Weak Cyp3a4 and P-Gp Inhibitors? JO - European Journal of Clinical Pharmacology VL - 77 IS - 9 SP - 1427 EP - 1428 PY - 2021 ER - |